Literature DB >> 15357965

Structure-activity relationships of epolactaene derivatives: structural requirements for inhibition of Hsp60 chaperone activity.

Yoko Nagumo1, Hideaki Kakeya, Junichiro Yamaguchi, Takao Uno, Mitsuru Shoji, Yujiro Hayashi, Hiroyuki Osada.   

Abstract

Epolactaene is a microbial metabolite isolated from the fungal strain Penicillium sp. It arrests the cell cycle at the G0/G1 phase and induces the outgrowth of neurites in human neuroblastoma SH-SY5Y cells. In this communication, we report the structure-activity relationships (SARs) of new epolactaene derivatives, including those lacking the epoxylactam moiety and having various side chains. These derivatives were evaluated for their ability to inhibit the growth of human cancer cell lines. They were also analyzed for their ability to affect human heat shock protein 60 (Hsp60), which we have already identified as a protein that binds to epolactaene. We also identified the important structural framework of epolactaene/ETB (epolactaene tertiary butyl ester) for not only binding to Hsp60 but also inhibiting Hsp60 chaperone activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357965     DOI: 10.1016/j.bmcl.2004.06.054

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Evidence for the rapid conversion of stephacidin B into the electrophilic monomer avrainvillamide in cell culture.

Authors:  Jeremy E Wulff; Seth B Herzon; Romain Siegrist; Andrew G Myers
Journal:  J Am Chem Soc       Date:  2007-03-31       Impact factor: 15.419

Review 2.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

3.  HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.

Authors:  Mckayla Stevens; Sanofar Abdeen; Nilshad Salim; Anne-Marie Ray; Alex Washburn; Siddhi Chitre; Jared Sivinski; Yangshin Park; Quyen Q Hoang; Eli Chapman; Steven M Johnson
Journal:  Bioorg Med Chem Lett       Date:  2019-02-28       Impact factor: 2.823

4.  Epolactaene binds human Hsp60 Cys442 resulting in the inhibition of chaperone activity.

Authors:  Yoko Nagumo; Hideaki Kakeya; Mitsuru Shoji; Yujiro Hayashi; Naoshi Dohmae; Hiroyuki Osada
Journal:  Biochem J       Date:  2005-05-01       Impact factor: 3.857

5.  Targeting the mitochondrial unfolded protein response in cancer: opportunities and challenges.

Authors:  Joseph R Inigo; Rahul Kumar; Dhyan Chandra
Journal:  Trends Cancer       Date:  2021-09-24

6.  Antitumor Activity of a 5-Hydroxy-1H-Pyrrol-2-(5H)-One-Based Synthetic Small Molecule In Vitro and In Vivo.

Authors:  Yunyun Geng; Xiaojian Wang; Luo Yang; Haili Sun; Yongqiang Wang; Yue Zhao; Ruiping She; Mei-Xiang Wang; De-Xian Wang; Jun Tang
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

Review 7.  Toward Developing Chemical Modulators of Hsp60 as Potential Therapeutics.

Authors:  Qianli Meng; Bingbing X Li; Xiangshu Xiao
Journal:  Front Mol Biosci       Date:  2018-04-20

Review 8.  Heat Shock Proteins in Alzheimer's Disease: Role and Targeting.

Authors:  Claudia Campanella; Andrea Pace; Celeste Caruso Bavisotto; Paola Marzullo; Antonella Marino Gammazza; Silvestre Buscemi; Antonio Palumbo Piccionello
Journal:  Int J Mol Sci       Date:  2018-09-01       Impact factor: 5.923

Review 9.  The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer.

Authors:  Abdullah Hoter; Sandra Rizk; Hassan Y Naim
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

Review 10.  Heat shock protein 60 and cardiovascular diseases: An intricate love-hate story.

Authors:  Indumathi Krishnan-Sivadoss; Iván A Mijares-Rojas; Ramiro A Villarreal-Leal; Guillermo Torre-Amione; Anne A Knowlton; C Enrique Guerrero-Beltrán
Journal:  Med Res Rev       Date:  2020-08-17       Impact factor: 12.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.